NCT05242042: JT001 (VV116) for the Early Treatment of COVID-19 |
|
|
| Terminated | 2/3 | 381 | RoW | JT001, VV116, Placebo | Shanghai JunTop Biosciences Co., LTD, Sponsor GmbH | Mild to Moderate COVID-19 | 03/23 | 03/23 | | |
NCT06560489: Pharmacokinetics and Efficacy of Multiple Dosing of LP-98 for Injection in HIV-infected Patients |
|
|
| Enrolling by invitation | 1/2 | 40 | RoW | Subjects will be randomly assigned to receive 1.25 mg, 2.5 mg, 5 mg, or 10 mg of LP-98. | Shanxi Kangbao Biological Product Co., Ltd., National Institute of Pathogen Biology， Chinese Academy of Medical Sciences | Hiv | 01/25 | 05/25 | | |
NCT06771479: A Study Evaluating the Safety and Immunogenicity of MVA Strain Monkeypox Attenuated Live Vaccine |
|
|
| Not yet recruiting | 1 | 120 | NA | MVA strain monkeypox attenuated live vaccine (low dose), MVA strain monkeypox attenuated live vaccine (high dose), Placebo | Shanghai Institute Of Biological Products | Monkeypox | 06/25 | 05/26 | | |
